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Chitosan as a biobased polymer is gaining increasing attention due to its extraor-
dinary physico-chemical characteristics and properties. While a primary use of
chitosan has been in horticultural and agricultural applications for plant defense
and to increase crop yield, recent research reports display various new utilizations
in the field of advanced biomedical devices, targeted drug delivery, and as bio-
imaging sensors. Chitosan possesses multiple characteristics such as antimicrobial
properties, stimuli-responsiveness, tunable mechanical strength, biocompatibility,
biodegradability, and water-solubility. Further, chitosan can be processed into
nanoparticles, nano-vehicles, nanocapsules, scaffolds, fiber meshes, and 3D
printed scaffolds for a variety of applications. In recent times, nanoparticles incor-
porated in chitosan matrices have been identified to show superior biological
activity, as cells tend to proliferate/differentiate faster when they interact with
nanocomposites rather than bulk or micron size substrates/scaffolds. The present
article intents to cover chitosan-based nanocomposites used for regenerative med-
icine, wound dressings, drug delivery, and biosensing applications.
KEYWORD S
chitosan, nanocomposites, nanoparticles, regenerative medicines and drug delivery
1 | INTRODUCTION
Nature-derived materials provide plenty of features to out-
compete man-made synthetic materials in various applica-
tions in industries ranging from cosmetics to aerospace.1
Concerning biomedical applications, natural materials are
often superior to synthetic materials due to their multiple
characteristics and properties.2–6 Among various natural
polymers, for biomedical applications water-soluble poly-
mers with salient biological characteristics are preferred
over polymers dissolving only in organic/inorganic sol-
vents.7 Chitosan is a polysaccharide and a chemical deriva-
tive of chitin. Henni Braconnot, a French professor, was
the first one who extracted chitin from mushrooms in
1811s.8 Later chitin was isolated from many invertebrate
animals such as mollusca, crabs, prawns shrimps,
crayfishes, and lobsters by various scientists. Among all,
shells of crabs and shrimps are the most abundant sources
for chitin. Chitins are polymers based on a disaccharide of
2-acetamido-2-deoxy-β-D-glucose linked by a β (1 ! 4)
bond. In the 19th century, chitosan was unveiled upon
deacetylation of chitin with abundant acetyl glucosamine
units.9 As a result, chitosan is a heteropolymer showing
both glucosamine as well as acetyl glucosamine groups
since the deacetylation is incomplete.10 The presence of
NH2 groups enables tailoring of the characteristics of this
polymer since they allow copolymerization using acrylic,
styrene, urethane, and vinyl ester-based monomers to
acquire supplementary properties.11–14 The chemical struc-
ture of chitin and chitosan is shown in Figure 1. Chitosan
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polymers are easily dissolvable at acidic conditions, unlike
chitin.18 The % content of glucosamine and acetyl glucos-
amine moieties dictates the properties of chitosan includ-
ing physico-chemical and biological characteristics.
Chitosan is biodegradable, analgesic, antibacterial, anti-
fungal, and hemostatic. Furthermore, the degree of
deacetylation (DD) influences the mucoadhesive charac-
teristics of chitosan.19 The number of products available
manifests the dominance of chitosan since 1995 compared
to other biopolymers including poly(L-lactic acid), colla-
gen, gelatin, or silk protein.20 Among various biopolymers,
chitosan is preferred for various biomedical products due
to its abundant biological properties like antimicrobial
activity, hemostasis, macrophage immune responses, capa-
bility to stimulate pro- and anti-inflammatory cytokines,
lipids, various growth factors and chemokines, polyelectro-
lyte complex formation, mucoadhesive strength, and
higher friability of tablets.21 Such multifunctional features
have not yet been reported for other biopolymers apart
from chitosan. Therefore, chitosan made an entry to vari-
ous medical applications including tissue regeneration,
drug delivery, biosensors, and wound dressings.
Various chemical routes have been used to modify
chitosan such as nitration, alkylation, sulphonation,
phosphorylation, xanthation, schiff's base formation,
acylation, hydroxylation, and graft copolymerization.12
Figure 1 displays some of the important steps involved in
the chemical modification of chitosan.
Recently, the properties of nanoparticles have made
them interesting for fabricating nanocomposites especially
for biomedical applications such as targeted delivery (drug
and gene), bioimaging, and regeneration of tissue like skins
and bone.22 Cells cultured on chitosan-based
nanocomposites proliferate fast, and such scaffolds pro-
mote cell differentiation without any growth factors, which
is very useful for tissue regeneration.23 For tissue
FIGURE 1 Top panel shows the
chemical structure of chitin (N-
acetylglucosamine) and chitosan, a
deacetylated chitin (N-acetyl-D-
glucosamine). Bottom panel shows
various important chemical
modification steps of chitosan:
(A) methylation, (B) thiolation,
(C) azylation, (D) co-polymerization
with acrylic monomer, (E) N-
succinylation (Reproduced with
permission from Jayakumar et al.,15
Shukla et al.,16 and Ravi Kumar
et al.17)
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engineering, developing a substrate or biomaterial imitat-
ing the cellular environment is one important key factor.24
A perfect biomaterial provides mechanical support as well
as simulates the cells to differentiate into specific cell types.
Nanocomposite substrates offer additional properties such
as antimicrobial or antifungal ones to avoid tissue damage
from infection/inflammation, which is one of the key fac-
tors hindering tissue regeneration upon implantation of
new tissue.25 One advantage of chitosan is that its surface
adsorbs proteins rapidly.26 Several articles reviewed the
biomedical applications of chitosan-based nanocomposites
in suspensions like nanogels and micelles.27–33 This article
reports on chitosan-based nanocomposite scaffolds with a




Many features such as cytotoxicity, mechanical properties
as well as healing efficiencies have to be considered while
fabricating a scaffold/substrate for tissue regeneration.
Various existing methodologies have been adapted for
processing of chitosan-based nanocomposites into films,34
fiber-meshes,35 hydrogels,36–40 and 3D printed constructs41
to mimic the 3D environment of tissues. Processing into a
freestanding thin film is the easiest choice and affordable
route to evaluate the physico-mechanical properties and
biocompatibility of the designed nanocomposites.42–44
Chitosan nanocomposite thin films can be fabricated
using solution casting, melt mixing, and in-situ nanoparti-
cle synthesis approaches. Solution casting is usually car-
ried out using water, cell culture medium, and sometimes
organic solvents. Additionally, ultrasonication is often
used to disperse the nanofillers effectively.45 Twin-screw
extruders, injection molding, and blow molding have been
used for melt mixing approaches in order to fabricate
chitosan nanocomposites.46 In an in-situ method, chitosan
has been used as a surfactant for the synthesis of
nanoparticles. These approaches do not need a large quan-
tity of materials, and any kind of shape and size can be
manufactured.47 The surface characteristics of freestand-
ing films can be fine-tuned by different post-treatment
techniques. Owing to its outstanding mechanical and bio-
logical properties, chitosan nanocomposite films have
already been used in various biomedical applications
including wound dressing patches,48–51 drug delivery,52,53
implant coatings,54–56 and as scaffolds.57,58 Various
nanoparticles such as nanoclay,59 graphene,60 silver,61 cel-
lulose whisker,62 and titania63 have been used for the
preparation of chitosan nanocomposites films for such
applications.
Beyond films, chitosan-based hydrogels are fascinat-
ing biomaterials, as they possess a high amount of water,
which makes them well compatible with most of the
native tissues.7,38,40,54 Gels comprise up to 10% solid-
phase in a total volume of the gel (the rest is water or liq-
uid phase). This 10% solid phase warrant the consistency
of the gel. Most importantly, hydrogels are mostly very
soft in nature and often self-recoverable in shape, which
will be useful during, for example, implantation. Besides
that, mechanical responses of hydrogels are likely to imi-
tate that of native soft tissues, which will make it easier
to assure the functional characteristics of the tissue to be
repaired.16,36,37,39 This is one major reason why hydrogels
are used as scaffolds in biomedical applications. Nano-
particle incorporation into a chitosan matrix enhances
mechanical strength, shape recovery, and stimuli-
response of chitosan-based hydrogels.
Sponges are a scaffold morphology with plenty of
micron sized open pores. The open pores can intake a
large number of fluids beneficial for cell growth as well
as proliferation.64,65 Chitosan-based nanosponges can be
fabricated by many techniques such as freeze-drying
(lyophilisation) and by introducing foaming agents dur-
ing melt mixing of chitosan and nanoparticles.65,66
Among them, a simple and efficient process is
lyophilisation, which starts with freezing a solution of
chitosan with or without additives followed by evapora-
tion of the solvent under reduced pressure.67,68
At present, there are numerous techniques available
to fabricate a chitosan-based membrane or scaffold for
tissue engineering such as particle salt leaching,69,70
electrospinning,71,72 stereolithography,73,74 gas
foaming,75,76 freeze-drying,57,67,75 and 3D bioprinting.77–
80 Electrospinning is a simple, straightforward, and cost-
effective technique for producing nanofibers. In a typical
electrospinning set-up, high voltage is applied from a
polymeric solution to draw fibers toward a grounded col-
lector.72 The spinning characteristics and efficiencies can
be improved by incorporating nanoparticles into chitosan
solutions as this can change the solution properties like
conductivity and viscosity, which inherently improves
the spinnability of the polymer dope.29,71 3D bioprinting
has exciting prospects since it shows many advanced fea-
tures like the capability of printing tissue-analog struc-
tures, or constructing 3D scaffolds with more than two
types of cells within a suitable matrix, which can bring
extraordinary functional characteristics and provide
faster tissue regeneration.77,80 The main concept of pro-
ducing 3D tissue constructs using bioprinting is based on
additive manufacturing approaches to construct a com-
plex structure, which mimics the parent tissue via a
layer-by-layer method.79 Depending on the type of bio-
printer, the choice of materials can be varied. The design
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protocol for printable materials plays a key role in print-
ing characteristics. The water-soluble nature of chitosan
biopolymer made it easy to assemble hydrogels at certain
pH values and temperatures, which showed properties
useful for 3D bioprinting.78 So far, very few researchers
have explored chitosan-based nanocomposite bioinks for
3D printing but the number of reports is raising. In the
subsequent sections, various aspects of chitosan
nanocomposites for tissue engineering applications are
discussed in detail.
2.1 | Chitosan nanocomposites for bone
engineering
At present, a large number of patients requires organ
transplantation including bone, heart, liver, kidney, and
so forth.81 Tendons, ligaments, skin, heart valves, blood
vessels, and bones are the most commonly transplanted
organs in the world.82 Taking bone as one example,
transplanting bone in patients above 50 years old is a sig-
nificant clinical challenge faced by orthopedics. Even
though bone has a certain healing ability, large defects
caused by age, traffic accidents, and bone tumor re-
section prevent good bone regeneration. Therefore, novel
approaches for repairing bone defects have to be devel-
oped. Bone is composed in its majority of pentacalcium
phosphates, collagen, several other proteins, as well as
cells such as osteoblasts, osteocytes, and osteoclasts.83
The major function of bone is to provide a skeleton with
load-bearing capacity and to protect the internal organs.
Bone experiences a constant cycle of resorption and rem-
odeling.84,85 Although, our body can constantly repair
bone tissue defects, larger defects need medical treat-
ment. Traditionally, autografts, allografts, and xenograft
are used in clinical practice to restore/repair damaged tis-
sues.86 Among these, autografts are considered the gold
standard, for which cells from the injured person are
harvested to repair or restore the damaged tissue.87 How-
ever, autografts have some limitations such as low avail-
ability, discomfort, scar formation, and donor site
morbidity. In allografts, cells from other persons than the
patient but of the same species and in xenografts, cells
from a different species such as pigs are used to repair or
restore tissues. These grafting methods are risky because
of possible tissue rejections, mismatching, and disease
transmission.88 The basis for choosing a fitting biomate-
rial for bone tissue engineering is a thorough understand-
ing of bone anatomy and the healing process. Bone
healing is a complex process, and the recovery and suc-
cess rate vary from person to person. Recent develop-
ments in bone tissue engineering use three-dimensional
(3D) processing technologies, which provide mechanical,
cellular, and molecular enviroments to repair, retain, or
recover injured bone tissue.
In the context of choosing fitting biomaterials, chitosan
nanocomposites with nanofillers like
hydroxyapatite,75,89,90 bioactive glass,23,91 zeolite,92 copper
nanoparticles,93 and carbon filler,27,43,93 and so forth are
extensively used for bone tissue engineering applications
and they are applied as thin films, fiber-meshes, scaffolds,
and hydrogels.94 Chitosan nanocomposites of choice for
bone engineering applications are summarized in Table 1.
Cao et al.140 prepared 2-N,6-O-sulfated chitosan/cal-
cium phosphate nanocomposite hydrogels loaded with
bone morphogenetic protein 2 (BMP-2) for the regenera-
tion of critical-size bone defect in rabbits showing
enhanced vascularisation. An in vitro alkaline phospha-
tase (ALP) assay confirmed the activity of released
BMP-2 from the developed hybrid gel after 3 and 7 days
of delivery. The robust angiogenesis of the prepared
hybrid gel was confirmed by both in vitro as well as
in vivo tests in the critical-sized defect (18 mm radius) of
the rabbit. Blood vessel formation was thoroughly investi-
gated using synchrotron radiation-based micro-computed
tomography imaging, three dimensional micro-
computed tomographic imaging, histological analysis,
immunohistochemistry, and biomechanical measure-
ments. Figure 2 shows micro-computed tomography
images used for quantitative analysis of new bone
(NB) formation followed by the amount of blood vessel
formation for various samples. μCT results revealed that
hybrid gels displayed the best performance concerning
vascularisation as well as volume of NB formation. The
results implied that BMP 2 alone is not able to augment
the blood vessel formation in the defect. The BMP-2/
SNP/G hybrid facilitated formation of more blood vessels
as well as larger volumes of NBs by faster biomineraliza-
tion. The improved angiogenesis was confirmed by study-
ing the relative gene expression of endothelial markers
such as endothelial cell differentiation (CD31) and endo-
thelial cell–derived von Willebrand Factor (vWF) assayed
using real-time quantitative reverse transcription poly-
merase chain reaction (qRT-PCR) at day 7. Histopathol-
ogy using hematoxylin and eosin (H&E) staining
(Figure 3) revealed the formation of blood cells (BC) and
macrophages (yellow line) at 2 weeks after implantation.
At four-week post-implantation, the development of cho-
ndrocytes (CC) was noticed. After 8 weeks, a larger vol-
ume of NB was observed in case of hybrid gels. More BC,
macrophages, OC, and NB were found in that experimen-
tal group compared to the other samples.
There are many reports on mechanical properties of
chitosan-ceramic nanocomposites and their comparison
to various human bone tissues.141–145 Xiao et al.142 stud-
ied the mechanical properties of hydroxyapatite
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TABLE 1 Chitosan nanocomposite substrates for bone engineering
Nanocomposites additives
Fabrication method and
chitosan details (if available)
Features in comparison to
pristine chitosan materials








Solution casting/Mw of 100,000–
300,000 g/mol and 85% DDA
• Antimicrobial activity and
hydrophilicity
Human lung fibroblasts (WI-38),
cell viability was above 80%





helped for cell localisation
Tobermorite type nanoclay96 Solvent casting/low-molecular-
weight
• Bioactivity and biodegradation MG63 human osteosarcoma
cells, cell viability enhanced up
to 30%.
• Cell compatibility
Nano bioglass embedded in
chitosan–polycaprolactone
bilayered films97
Solution casting • Mechanical properties,
bioactivity, and biodegradation
MG-63 osteoblast-like cells, cell
viability was 98% for
monolayer films• Cell viability was higher for
monolayer films
Bioactive glass nanoparticles98 Solution casting/Mw of 190,000–
310,000 g/mol, 75%–85% DDA,
and a viscosity of 200–800 cps
• Cell metabolic activity,
proliferation, calcium
deposition, DNA content, and
biomineralization
Human periodontal ligament






Solution casting/Mw of 230,000 g/
mol, and 86% DDA




Human osteoblastic MG-63 cells,
cell viability up to 55%
• Excellent biocompatibility and
>5% hemolysis
Copper nanoparticles100 Solution casting/low-molecular-
weight chitosan, which has 85%
DDA
• Remarkable anticancer effect
due to a higher amount of
mitochondrial reactive oxygen
species (ROS and enhanced
caspase activity)
Human osteosarcoma cell line
MG-63, 85% cells were dead
upon incorporation of copper
nanoparticles
Hydroxyapatite and silica101 Solution casting/85% DDA • good apatite layer formation,





reinforced chitosan and poly
(vinyl alcohol), PVA
blends102
Solution casting/Mw of 230,000 g/
mol with 86% DDA
• Excellent mechanical properties
such as tensile strength, %
elongation, modulus, % cell
viabilities and rate of cell
proliferation
Human osteoblastic MG-63 cells,
cell viability was increased up
to 15%





increased by 377%, collagen I
increased by 479, and
osteopontin increased by 597%
Mesenchymal stem cells (MSCs),




weight and 75%–85% DDA
• Enhanced mechanical
properties, antimicrobial
activities, rate of biodegradation,
cell penetration, adhesion and
spreading efficiency.
Rat osteoprogenitor cells and
human osteosarcoma cells




chitosan details (if available)
Features in comparison to
pristine chitosan materials












Human osteoblasts like MG-63




Solution casting/Mw of 90,000–
150,000 g/mol and 80% DDA
• Enhanced tensile strength and
elastic modulus, antibacterial
activity (>77%), high cell
viability.
Human mesenchymal stem cells,
cells viability was up to 90%
• Above 5 wt% GO reinforcement





Solution casting/Mw of 500,000 g/
mol with 70%–90% DDA
• Decreased % water uptake,
retention ability and bio
degradation for the
nanocomposites.
Human osteosarcoma cell line
(MG-63 cells), cell viability
increased by 2-fold







In situ approach followed by
solution casting/Mw of
1,000,000 g/mol with 95% DDA
• Superior mechanical strength
observed for the nanocompsoites
blend.
MC3T3-E1 cells, cell proliferation
increased by 21/4-fold
• Cell adhesion found to be
almost similar and cell
proliferation was slightly higher
Chitosan scaffolds (sponges, hydrogels, etc.)











showed non-toxicity at lower
concentrations of silicon
dioxide and zirconia nano
particles encapsulation.
Hydroxyapatite110 Solution method/Mw of 310,000 g/
mol with 90% DDA
• In vitro cell uptake and
proliferation was superior
Preosteoblasts (MC3T3-E1)
• In vivo study confirmed the new
bone formation, trabecular






• Improved antibacterial activity
against both gram-positive and
gram-negative bacterial strains.
Rat osteoprogenitor cells and
human osteosarcoma cell line
• No toxicology effect and high
rate of biodegradation
In situ developed nano
hydroxyapatite111
Co-precipitation technique
followed by freeze drying
method/93.5% DDA
• Enhanced biocompatibility Clonal preosteoblastic cell line
MC 3 T3-E1 cells. Cell viability
increased up to 6-fold after
7 days of culture.
Nanocrystalline calcium
phosphate112










Freeze-gel approach/85%DDA • Adequate compressive strength,
improved metabolic activity,
higher wettability, great extent
of mineralization
Human mesenchymal stem cells
(hMSCs). Cell viability
increased up to 2-fold after
5 days of culture.
(Continues)




chitosan details (if available)
Features in comparison to
pristine chitosan materials




Dual nanofillers of bioactive




• Enhanced compression strength,
biodegradability, wettability,
mineral deposition and cell
compatibility




derived from waste mussel
shells115
Freeze-drying method/chitosan
derived from waste arrow squid
pen (Nototodarus sloanii) had
75% DDA
• Enriched biodegradability of






Cell viability increased by
2-fold for L929 and 5-fold for
Saos-2
Bioglass116 Needle punching process • Exhibited higher porosity of
about 86% without affecting its
mechanical stability.
Human bone marrow stromal
cells (hBMSCs), cell viability
increased by 4-fold after 7 days
of culture.• Improved cell adhesion and
proliferation
Nano-hydroxyapatite117 Freeze-drying method/80% DDA • In vivo and 3D-μCT results
showed ectopic osteogenesis, De
novo bone, biodegradation and
collagen formation were found
to be greater




Freeze-drying method • The releasing spare amount of
gadolinium ions (Gd3+) helped
to enhance cell viability or
proliferation differentiation of
stem cells toward osteogenic
lineages such as improved ALP
activity, Runx-2, osteocalcin
secretion and Col-I expressions




• In vivo results showed new bone
formation, with dense collagen




Freeze-drying method • Nanocomposites showed
prominent expression levels of
osteogenic lineages including
osteocalcin, COL1, Runx2 and









Nano-hydroxyapatite120 Freeze-drying method/91.2% DDA • Excellent regeneration ability of
critical-sized calvarial bone
defect (in vivo)
Only in vivo assessment
• New bone formation and
neovascularisation were also





Hydrogels prepared by complex
coacervation method and
photopolymerisation. The
chemically modified 2-N, 6-O-
sulfated chitosan was obtained







ectopic bone formation, larger
amount of new bone formation
and induced reunion of the bone
marrow cavity
Human mesenchymal stem cells
(hMSCs) and Human
umbilical vein endothelial cells
(HUVECs). Cell proliferation
was enhanced up to 180% after
7 days of culture.




chitosan details (if available)
Features in comparison to
pristine chitosan materials









Solution blending method • Nanocomposite hydrogels




Mesenchymal stem cells. Cell
viability increased up to 5-fold
after 7 days of culture.






chitosan had a degree of
polymerization of above 400
• Decreased % porosity and
swelling ratio
MC-3 T3-E1 cells, cell viability
enhanced up to 90%
• Enhanced biodegradation rate






Foaming method by bead form/Mw
of 100,000–300,000 g/mol
• Composite scaffolds displayed
porosity of 82%, and excellent
hydrophilicity, biodegradability.
Osteoblast cells. Cell viability
increased up to 11/4-fold.
• Better cell attachment and







100,000–150,000 with 85% DDA
• Nanocomposite scaffold showed
controlled swelling and
degradation rate and excellent
biomineralization
Osteoblast-like cells (MG-63),
fibroblast cells (L929), and
human mesenchymal stem




• Improved cell uptake, adhesion
and proliferation with the
various types of cells
Nano-hydroxyapatite
incorporated into the blends
of chitosan and
carboxymethyl cellulose126
Freeze-drying method/two types of
chitosan used average Mv of
250,000 g/mol with 80% DDA
and carboxymethyl cellulose - Na
degree of substitution around 0.7














250,000 g/mol with 90% DDA
• Enhanced compression modulus
from 15.4 to 25.5 MPa, strength
from 1.42 to 1.63 MPa
Rabbit marrow mesenchymal
stem cells (MSCs)
• Improved rate of
biodegradation, ALP activity
and osteoconductivity




of DDA with 20–300 cPs viscosity
• Nano silica facilitated the




viability increased up to
½-fold.
• Enhanced the apatite layer
formation and no significant
toxicity found even at higher
doses of SiO2 incorporation.
• Nano silica encouraged
differentiation ability
(osteolineage) of the





100,000 to150,000 g/mol with
85% DDA
• Reduced biodegradability as well
as swelling ratio.
MG-63 cells








chitosan details (if available)
Features in comparison to
pristine chitosan materials








Average Mw of 200,000–
250,000 g/mol with 95.41% DDA
• No change was observed for %
cell viability between control
chitosan/cellulose blend
membrane
Primary osteoblast cells. Cell
viability enhanced up to
12-fold after 11 days of culture
for the nanocomposites




infiltration of bone tissues (in
vivo) that led to better
osteointegration, remodeling
















increased up to 4-fold after
11 days of culture.




modified chitosan had a
medium-average Mw, 200-800 cP
viscosity with 75–85% DDA
• Exhibited higher porosity,
higher water retention capacity,






• Biological activities were
enhanced such as cell viability,
proliferation, mineralization,
new bone formation (in vivo).
• Robust stem cell differentiation
into osteogenic lineages like
expression level of collagen type








Mw of 188,000 g/mol with 80%
DDA
• No burst release, sustained as
well as enhanced cumulative
drug release (95%) were found




• Slightly improved mechanical
properties, and marginal
improvement in biodegradation,
cell viability, proliferation, drug
release, alkaline phosphatase
(ALP) for the nanocomposite
sponges.





Solution approach/average Mw of
250,000 g/mol with 95.6% DDA
• Incorporation hydroxyapatite
nanoparticles enhanced % cell
viability, new bone formation
and collagen deposition
Allogeneic bone marrow derived
mesenchymal stem cells














Primary murine osteoblast cells,
cell viability enhanced up to
90%
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reinforced polycaprolactone–chitosan nanocomposites,
and their tensile modulus was enhanced significantly com-
pared to pristine polycaprolactone–chitosan samples pre-
pared using a melt mixing approach. The mechanical
properties such as tensile modulus and compression mod-
ulus of chitosan–gelatine based nanocomposite scaffolds
were improved by 2-fold upon reinforcement with dual
filler nanohydroxyapatite- nanoclay (montmorillonite).141
Sun et al.143 investigated the mechanical properties like
tensile modulus and indentation hardness of chitosan/
nanodiamond nanocomposites. The tensile modulus and
indentation hardness of chitosan nanocomposites was
enhanced by 343% and 127%, respectively upon 5 wt%
nanodiamond filler loading. Comparative studies of the
mechanical properties of porous chitosan nanocomposites
scaffolds with various nanoparticles such as hydroxyapa-
ptite, nano-zirconia, nano-calcium zirconate was carried
out by Gaihr et al.144 Among all, nano-calcium zirconate
reinforced chitosan nanocomposites scaffold registered
best mechanical strength like 5-fold improvement in com-
pression modulus and 2.5 fold improvement in young's
modulus. Caridade et al.145 investigated the dynamic
mechanical properties of bioactive glass nanoparticles
reinforced chitosan nanocomposite membranes after
simulated body fluid immersion. Biomineralization and
dynamic mechanical strengths like storage modulus (E0)
and Tan δ were enhanced marginally for the chitosan
nanocomposite membranes upon incorporation of bioac-
tive glass nanoparticles.
Jiang et al.130 fabricated spiral-cylindrical shaped
nanocomposite scaffolds based on nano-hydroxyapatite
incorporated into blends of chitosan and cellulose for
bone regeneration applications. An in vitro MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] assay suggested that there was no change con-
cerning cell proliferation between the control sample and
nanocomposites after 5 days of culturing. However, there
was an increased cellular uptake and osteocalcin expres-
sion upon incorporation of 60-wt% of nano-
hydroxyapatite filler into the blends. In vivo experiments
with New Zealand white rabbits showed prominent
improved osseointegration, complete infiltration of bone
tissues, and NB formation in presence of the
nanocomposite scaffolds compared to the control group.
These features may facilitate the remodeling and rebuild-
ing of bone defects rapidly. Figure 4 shows the key find-
ings presented by X-ray photographs, 3D micro-CT




chitosan details (if available)
Features in comparison to
pristine chitosan materials







Dip-coating approach • Nanocomposites coating
improved the hydrophilicity, %
hemolysis, protein adsorption,
biomineralization (apatite
formation) and cell viability of
titanium surfaces
MG 63 osteoblast cell lines
Hydroxyapatite nanohybrid on
porous carbon fiber137
Dip-coating approach • Nanohybrid coatings
encouraged biomineralization,
cell adhesion, spreading, and
proliferation of porous carbon
fiber felts.
Human bone marrow stromal
cells, cell viability enhanced up
to 4-fold
Silver and hydroxyapatite dual
nanoparticles on TiO2
substrate138
Anodization • Nanocomposite coating showed
prominent antimicrobial
microbial efficacy against Gram-










Medium-average Mw of 80,000 g/




and hydrophilicity of titanium
substrate
-
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the control groups as well as the nanocomposite scaf-
folds. These combined results confirmed that the fabri-
cated substrate is a suitable candidate for bone tissue-
regeneration.
2.2 | Chitosan nanocomposites as wound
dressings
In general, discontinuity in the skin occuring because of
external laceration (accident) is called a wound. The
wound is classified in two major categories depending on
healing rates. An acute wound heals faster, and a chronic
wound takes more time to heal due to bacterial burden
and larger discontinuity as two out of several factors.
Wound healing has four stages namely hemostasis,
inflammation, cell proliferation, and remodeling. Wound
regeneration is a dynamic process comprising the secured
action of inflammation, vascular as well as connective tis-
sue production. Many biomaterials have been tested as
wound dressings for acute and chronic wounds. The rate
of healing varies depending upon the characteristics of
the used biomaterials. Biomaterials should protect the
wound from subordinate infections, absorb the wound
fluids, support the tissue mechanically, avoid
wound dehydration, and support cell differentiation.
Chitosan-based nanocomposite substrates have received
quite some attention due to various salient features such
as excellent microbial rejection, O2 permeability,
photothermal effects, stimuli-responsiveness, and easy
handling. It is able to process chitosan nanocomposites
into thin-films, hydrogels, and fiber-meshes. The proper-
ties and characteristics of chitosan nanocomposites are
better when the amount of nanoparticles is increased.
Various nanoparticles including silver, iron, copper, zinc
hydroxyapatite have been used as fillers for wound dress-
ing applications. The various morphologies of chitosan
nanocomposites and their key properties in context of
wound dressing applications are summarized in Table 2.
Nirmal et al.159 fabricated injectable nanostructured
chitosan hydrogels with incorporated tigecycline and
platelet-rich plasma for the treatment of infected wounds.
Flow behavior as well as macroscopic observation of gel
formation at various time points is shown in Figure 5.
The rheological characteristics of the hybrid nanogels (tg-
ChNPs-ChPRP) such as shear thinning improved the
injectability. In an in vitro wound closure study using
L929 cell migration best results were obtained in the pres-
ence of tg-ChNPs-ChPRP gels concerning antibacterial
behavior, cell compatibility, hemocompatibility, drug
release, and blood clotting characteristics. In vitro scratch
wound closure studies are displayed in Figure 6 for a bet-
ter understanding of the wound regeneration characteris-
tics of the developed chitosan nanocomposites.
2.3 | Chitosan nanocomposites for drug
delivery
Chitosan nanocomposites are often used in drug delivery
applications to treat various diseases including cancer or
osteoarthritis.161 Drug embedded nanocomposites exhibit
multifunctional properties such as excellent pharmacoki-
netics by delivering drugs at the desired site or tumor.
FIGURE 2 (A) Three dimensional micro-computed
tomographic (μCT) images of various 2-N,6-O-sulfated chitosan-
based nanocomposite sponges placed in two different regions of
interest (ROI) in rabbits analyzed 4 weeks after implantation in
comparison to a gelatin sponge. This images show the integration
of new bone and vessel formation. ROI 1 reflects a cylindrical
portion (30 mm height and 20 mm diameter) involving the radius
and adjoining ulna with the defect site at the center and ROI 2 a
cylindrical portion (18 mm in height) involving only the radius
with the defect site at the center, (B) Quantitative determination of
bone mineral content and blood vessel volume from μCT showing
high numbers for the nanocomposite sample compared to that of
others including the gelatin sponge. Gelatin sponge (G), bone
morphogenetic Protein-2 (BMP-2), 2-N,6-O-sulfated chitosan
26SCS), and 2-N,6-O-sulfated chitosan nanoparticle (SNP)
(Reproduced with permission from Cao et al.140)
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Stimuli-responsiveness helps to fine-tune drug release
rates and avoids burst drug release. Drugs can be embed-
ded efficiently in chitosan-based materials.1 Chemical
modifications of chitosan are one option to vary the
amorphous nature of the materials with impact on drug
loading efficiency and release characteristics.7,17,28 Litera-
ture shows that there are many nanoparticles including
reduced graphene oxide,162 nanoclays,163 gold
nanoparticles,164 mesoporous zeolites,165 layered double
hydroxide,166 hydroxyapatite,167 iron nanoparticle,168 and
SiO2 nanoparticles
169 used for the fabrication of various
types of chitosan-based drug delivery carrier. 2D layered
nanosheets like MXenes (Ti3C2, Nb2C) nanoclay,
graphene or carbon nanotubes (CNT) display better
release characteristics due to the generation of tortuous
pathway for clays yielding sustained release characteris-
tics.170 Furthermore, various researchers have also
attempted to implement mesoporous silica and other
nanoparticles including hydroxyapatite in chitosan matri-
ces for fine tuning of drug loading efficiencies and release
characteristics.171–174 Their results suggest that pore size
of the nanoparticles helped to encapsulate higher
amounts of drugs (up to 90%) as well as to regulate the
drug release at the desired site and time. Further, many
nanoparticles like Ti3C2, Nb2C, and carbon dots, CNT,
graphene oxide and GdPO4, and so forth have been used
as photothermal agents for treating various tumors in
NIR-I & NIR-II biowindows.175,176 They showed excellent
photothermal conversion efficiencies and rapid ablation
of tumors. The photothermal-transformation efficiency
FIGURE 3 Hematoxylin and eosin (H&E)-stained sections of various 2-N,6-O-sulfated chitosan-based nanocomposite sponges placed in
rabbits analyzed 2, 4, and 6 weeks after implantation compared to that of others including a gelatin sponge. The nanocomposite sponges
show large amount of new bone, chondrocytes, macrophages and improved vasculogenesis. The following abbreviations are used Mat:
implanted material; NB: new bone; BC: blood cell; G0: granulation tissue; CC: chondrocytes; LB: lamellar bone; yellow arrow: macrophages;
black arrow: vasculogenesis, O: osteon) (Reproduced with permission from Cao et al.140)
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of chitosan nanocomposite substrates helped to trigger
drug release (%) at the target tissue.176 A summary of
drug delivery applications based on chitosan
nanocomposites are compiled and summarized in
Table 3.
Zhang et al.188developed chitosan hydrogels with
incorporated magnetic nanoparticles and β-
glycerophosphate for the sustained and long-lasting deliv-
ery of bacillus calmettee guérin for the treatment of blad-
der cancer. Figure 7 shows the preparation of the
solution, its gel formation, drug encapsulation followed
by how the sample behaves under a magnetic field. An
intense and lasting CD4+ lymphocytic infiltration was
triggered in case of Fe3O4-BCG-CS/GP gels (group 4 sam-
ples). Figure 8 shows histological images of the various
groups after CD4 staining. Rats in group 1 had 631 ± 78
CD4+ T cells and in group 3 had 508 ± 43.3 CD4+ T
cells, whereas rats in group 2 had 2578 ± 268.7 CD4+
T cells and in group 4 had 3913 ± 466.7 CD4+ T cells
showing multifocal lymphocytic infiltration. The results
revealed that Fe3O4-BCG-CS/GP gels (group 4) had
higher levels of CD4+ T cells infiltrating the submucosa
when compared to rats of the other groups. This result
has been corroborated by the analysis of urinary cyto-
kines as well and provides a first basis for antitumor
treatment and induced high local immunity in the
bladder.
Chandran and Sandhyarani180 fabricated electric field
responsive nanocomposite thin-films made of chitosan/
gold nanoparticles and encapsulated 5-Fluorouracil (5-FU)
by solution casting. The fabricated nanocomposites
exhibited a higher drug release efficiency (63%) and
sustained-release controlled by an external electric field
(DC) in an electrolyte solution. The % human cervical can-
cer cell death was extremely high (above 90%) showing the
efficiency of the anticancer effect.
Shah et al.,148 fabricated chitosan/silver nanoparticle
composite films with embedded moxifloxacin drugs by
in-situ co-precipitation. The drug-encapsulated nano-
composite films exhibited excellent mechanical proper-
ties as well as antimicrobial efficacy against the various
pathogens. They also exhibited a higher swelling ratio, as
FIGURE 4 (A) X-ray
radiographic photographs and three
dimensional micro-computed
tomographic (μCT) images of
biomimetic spiral-cylindrical
scaffolds based on blends of
chitosan/cellulose placed in a
concave defect in rabbits and
analyzed at 4, 8, and 12 weeks after
implantation. Comparison with a
control scaffold showed new bone as
well as callus tissue formation.
(B) Hematoxylin and eosin (H&E)-
stained sections of nanocomposite
scaffolds implanted in rabbits
analyzed at 4, 8 and 12 weeks to
show the bone marrow and new
bone formation (lower panel is the
magnified portion of the red
squares, which are marked in the
upper panel). HB, NB, FT, BM, and
M designates host bone, new bone,
fibrotic tissue, bone marrow, and
scaffold, respectively (Reproduced
with permission from Jiang et al.130)
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TABLE 2 Chitosan nanocomposite substrates for wound dressing
Nanocomposites additives
Fabrication method and
chitosan details (if available)
Features in comparison to
pristine chitosan materials





in blend of chitosan-silk
fibroin, Bombyx mori146
Solution casting/95% DDA and
chitosan-silk fibroin ratio was
1:2
• Enhanced moisture retention
capability, tensile strength and
antimicrobial characteristics
No in vitro evaluation, only in
vivo assessment
• In vivo studies showed
controlled release of silver
nanoparticle detected in liver,
spleen and kidney, accelerated
wound healing, reformed





In situ generated silver
nanoparticles/various types
of chitosan147
In situ approach/three types of
chitosan with low Mw of
369,000 g/mol, medium Mw of
1,278,000 g/mol and high Mw
of 2,520,000 g/mol with varied
DDA of 86%, 89%, 85%,
respectively
• Chitosan served as a reducing
and stabilizing agents of metal
oxide precursors
Mammalian somatic (HaCaT)
and Tumoral (A549) cells,
cell viability was above 80%
for both cells.• Nanocomposites showed
pronounced antimicrobial
activity against Gram- (+) as
well as Gram- () bacteria





chitosan and sericin (Bombyx
mori) blend films148
Solution blending/low Mw with
85% DDA
• Nanocomposite films
promoted controlled release of
drug with higher loading/
releasing efficiency.





activity and full thickness
wound healing efficiency by
observing the formation of
fibrosis, collagen fiber bundles
reorganization,
neovascularization, and thick
epidermal layer (in vivo
results)
Layer-by-layer (LBL) fabricated






chitosan derived from shrimp
shells, which has average Mw
of 200,000 g/mol with 92%
DDA
• Nanocomposite scaffolds
showed great zone of
microbial inhibition enhanced
the cell compatibility at lower
concentration of nanofiller
loading
Human epidermal (EP) cells,
cell viability was enhanced
up to 2-fold.
Silver nanoparticles-
encapsulated into blends of









capability, and water vapor








chitosan details (if available)
Features in comparison to
pristine chitosan materials









MW of 100,000–150,000 g/mol
with 85% DDA. Chitosan and





toxicity and robust cell
proliferation of the
nanocomposite sponges
Human dermal fibroblasts, cell
viability were about 75%.
Nano chondroitin sulfate




Mw of 100,000–150,000 g/mol
with 85% DDA. Chitosan-HYA
blend ratio is 2:1
• Ternary nanocomposites
showed enhanced % swelling
and blood clotting ability
along with excellent cell
compatibility
Human dermal fibroblasts, cell
viability were about 90%.
Sponge-like microporous
chitosan reinforced with
silver and zinc oxide
nanorods153
Lyophilization process/average
MW of 179,000 g/mol with
≥95% DDA
• Nanocomposite sponges
displayed 88% of porosity,
higher swelling ratio, and
enhanced blood-clotting
capability too.
Cellosaurus cell line (L02), cell
viability was 95%.
• Significantly enhanced the
antimicrobial activity (In vitro









Combination of oxidation and
freeze-drying approach/
chitosan derived from crab
shells having average Mw of
235,000 g/mol with 93.7%
DDA




robust cellular uptake as well
as cell proliferation
L929 murine fibroblast cell
line, cell viability was above
90%.
• In vivo results depicted that
enhanced healing rate of
cutaneous wound followed by
better mature epidermization







Mw of 100,000–150,000 g/mol
with 85% DDA





Only in vivo assessment













ratio, and higher water
retention %, significant
inhibition for the bacterial
growth
L929 cells, cell viability was
above 90%
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well as prolonged drug release up to 36 h, improved bio-
degradability, and biocompatibility (in vivo) in compari-
son to control chitosan films. Likewise, other drugs such
as diclofenac sodium, doxorubicin (DOX), and 5-amino
salicylic acid have been encapsulated in chitosan thin-
films for cancer therapies.
Pifithrin-α (PFTα) was encapsulated in MgAl based lay-
ered double hydroxide reinforced chitosan nanocomposites
using freeze-drying.166 The nanocomposites showed a
sustained drug release profile with 95% cumulative release
but the initial burst release could not be prevented. How-




chitosan details (if available)
Features in comparison to
pristine chitosan materials





showed no cell cytotoxicity at
low concentrations of silver
nanoparticles incorporation.
• In vivo results proved that
wound contraction ratio,















showed controlled as well as
higher amount (60%) of VEGF
release.
Human dermal fibroblast
(HDF) cells and human
umbilical vein endothelial
cells (HUVECs). Cell
viability enhanced to 98%
after 48 h of culture.
• Also, an excellent cell
compatibility and capillary
like tube formation were
perceived for the HUVECs









had an average Mn of 30,000 g/




diminished % cell viability
MC3 T3 cells, cell viability
enhanced to above 90% after










exhibited excellent in vitro, ex





L929 cell lines, cell viability
increased up to 2-fold after













and collagen deposition (in
vivo) of the nanocomposite
hydrogels
No in vitro examination, only
in vivo was performed
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osteogenic differentiation were significantly enhanced in
PFTα-embedded nanocomposite scaffolds. In-vitro human
bone marrow mesenchymal stem cells (hBMSCs) prolifera-
tion was enhanced up to 3-fold and robust NB tissue forma-
tion was confirmed from in-vivo results.
2.4 | Chitosan nanocomposites for
miscellaneous tissue engineering
applications
Apart from the summarized applications in bone engi-
neering, wound dressing, and for drug delivery applica-
tions, chitosan nanocomposites have been also other
medical applications. They can be used as packaging
films for storing drugs,191 as coatings for metal electrodes,
and medical kits, cardiac tissue engineering, and
electroactive tissue engineering.192 Here, a selection is
shown of miscellaneous tissue engineering applications of
various chitosan nanocomposites which is summarized in
Table 4. Various nanoparticles such as
cetyltrimethylammonium bromide modified rectorite
(REC) layered silicate,185 iron,85 silver, and manganese
dioxides have been used to reinforce chitosan matrices for
fabricating antimicrobial packaging films. The
nanocomposite films showed excellent antimicrobial activ-
ity against gram-positive bacteria, gram-negative bacteria,
and fungi with fast killing rates and more than 90% effi-
ciency against several pathogens.
Jing et al.206 fabricated an electroactive hydrogel
made of chitosan/graphene oxide with self-healing capa-
bilities as well as shape recovery for muscle tissue engi-
neering applications. Polydopamine was tested as an
oxidizing agent, which is a mussel-inspired agent for the
FIGURE 5 Inversion test for gel
formation and improved rheological




(Reproduced with permission from
Nimal et al.159)
FIGURE 6 (A) Graphical
representation of the in vitro wound
closure experiment in a culture dish.
(B) Images of L929 cell migration
after 48 h of culturing in the




concentrations of PRP compared to
that of a control chitosan gel.
(C) Area of % scratch wound closure
of the nanocomposite hydrogel
compared to that of a control
chitosan gel (Reproduced with
permission from Nimal et al.159)
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TABLE 3 Chitosan nanocomposite substrates for drug delivery
Nanocomposites additives
Fabrication method and
chitosan details (if available)
Features in comparison to
pristine chitosan materials











weight of 50,000–190,000 g/
mol with 85% DDA
• Nanocomposite films showed
excellent drug loading efficiency
of 93% for 5-FU and 95% for CU
and no burst release was observed
Human colon cancer cell lines
(HT-29) and mouse
embryonic fibroblast cells
(NIH 3 T3). Cell viability was
above 90% for fibroblasts
whereas 80% cells were deed
for HT-29
• The dual drug encapsulated rGO
nanocomposites enhanced
anticancer activity of killed 80%







molecular- weight with 85%
DDA
• The drug loading efficiency was
96% for nanocomposites films and
showed sustained release up
to 72 h
MCF-7 cell line, % cell viability










• 5-FU drug encapsulated
nanocomposite films with 30 wt%
loading of MMT showed excellent
performance in terms of loading
and releasing efficiency
-
• The burst release of drug was








Solution casting/average MW of
270,000 g/mol with 85% DDA
• The drug release characteristics of
nanocomposites were controlled
by the external electric field (DC)
in electrolyte solution
Human cervical cancer cell
lines SiHa, cell death was
above 90%.
• A higher drug release (63%) was
obtained for the nanocomposites
films at pH of 5.3 under external
electric field.
• The % cell death was extremely
high for the drug encapsulated
nanocomposites films, which





In situ solution casting/medium
average MW of 8,401,000 g/




many silent features such as
controlled and prolonged drug
release (up to 72 h and 54%
release) with pH dependent
manner
A549 cancer cells, cell death
was up to 80%
• It also exhibited excellent





In situ approach followed by
solution casting/low molecular






No in vitro examination, only
in vivo assessments
(Continues)




chitosan details (if available)
Features in comparison to
pristine chitosan materials




• It also exhibited higher swelling
ratio, as well as prolonged drug






Solution casting/98% DDA with
a viscosity of 12 mPa s
• Drug embedded clay
nanocomposites showed well
intercalated morphology that
enhanced the prolonged release
of drug up to 8 h with cumulative
drug release of 60%
-
• Initial burst release of drug from
nanocomposites films were
controlled by upon increasing the
addition of nanoclay as it induce




Solution casting as well as melt
mixing approach/chloro acetyl
modified chitosan having
average Mw of 400,000 g/mol
with 70% DDA
• The prepared nanocomposite by
both methods showed prolonged
drug release up to 80 h and drug
release efficacy was more than
90% with pH dependent.
Human tumor cell lines
(HCT15), cell death was
above 50%
• The % cell death was more than
50%, which revealed the










average Mw of 200,000 g/mol
with 92% DDA
• Drug loading efficiency and
sustained release characteristics
were enhanced upon
incorporation of clay in chitosan




• Cumulative drug release from
nanocomposites films was
significantly higher (85%) at basic





Solution casting • Nanocomposite films possessed
drug loading efficiency of 95.8%
with cumulative release of 88.6%
under the tumor tissue pH of 5.5
MG63 and Human bone
marrow derived
mesenchymal stromal cells
(hBMSCs), cell viability was
above 85% for both cell lines• Drug release was only 49% at
pH 7.4. and the cell compatibility
was also pronounced for the drug
encapsulated nanocomposites




chitosan details (if available)
Features in comparison to
pristine chitosan materials








Freeze-drying method • GS-loaded hydroxyapatite
microtube–CHS composites
scaffolds showed excellent
mechanical strength, high drug
loading capability (97%),
sustained drug release profile
with reduced initial burst release
Rat bone marrow stromal cells
(bMSCs), cell viability
increased up to 2-fold
• High antibacterial activity, cell
adhesion, and biomineralization
in comparison to hydroxyapatite
nanorod reinforced scaffolds due
to varied physical and





Freeze-drying method • Nanocomposites showed
sustained drug release profile
with 95% cumulative release but





was enhanced up to 3-fold
• Mineral deposition, cell viability,
proliferation and osteogenic
differentiation lineages such as
COL1, ALP content RUNX2, OPN
and OCN were significantly
enhanced in PFTα-embedded
nanocomposite scaffolds




Facile in situ hybridization
method
• Fabricated magnetic hydrogels
tenuously changed the drug
release from passive release to
pulsatile release under a low
frequency alternating magnetic




modulus compared to that of
pristine chitosan hydrogels
MG-63 cells, cell viability was
87%







average MW of 50,000 g/mol
with 95% DDA
• Prolonged intravesical Bacillus
Calmette–Guérin (BCG)
residence time under magnetic
field for the nanocomposite
hydrogels
No in vitro examination, only
in vivo was performed
• Improved antitumor effect as well
as local immune activity was
observed for the nanocomposite
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preparation of graphene oxide. The conductive graphene
oxide significantly altered or improved cell viability as
well as cell proliferation of human embryonic stem cell-
derived fibroblasts and cardiomyocytes in the
nanocomposites in comparison to pristine chitosan
hydrogels. The impulsive beating rates of cardiomyocytes
on the nanocomposites were two fold higher than the
usual rate on tissue culture grade polystyrene (TCPS).
Hence, conductive hydrogels can open new routes in
modern muscle tissue engineering specifically in electri-
cally active tissue like muscle, nervous or heart. They can
help in regenerating the repaired tissues as well as inte-
grate with the native tissue instantly.
Shao et al.207 prepared chitosan sponges with incorpo-
rated silver sulfadiazine nanomaterials using a freeze-
drying approach. The surface morphology of variously
prepared sponges is shown in Figure 9. The cross-
sectional view clearly shows the open porous three-
dimensional network architecture of the sponge as well
as the uniform pore sizes. The nanocomposites showed
increased swelling ratios, porosity, and antimicrobial
characteristics along with improved cell viability of
human embryonic kidney 293 cells. However, there was
an abrupt change in the cell morphology upon increasing
the number of nanosilver particles above 5%. It is specu-
lated that this is due to toxic effects.
Mitra et al.198 fabricated copper-loaded acrylated
quaternized chitosan/silica antibacterial coatings on
poly(vinyl fluoride) films to impart antimicrobial activity.
The nanocomposite coatings showed exceptional antimi-
crobial efficacies with 99% pathogen killing, and at the
same time dermal fibroblast viability was enhanced up to
95%. The conductivity of chitosan nanocomposites has
been effectively used for cardiac tissue engineering by
incorporating novel conducting nanoparticles like CNT,
graphene oxide, and carbon dots.
Pok et al.200 fabricated nanocomposites by embed-
ding single-walled CNT (SWCNT) in gelatin-chitosan
blends. SWCNT showed some toxic effects upon
increasing the dosage. At 175 ppm of SWCNT, the scaf-
folds showed only 47.7 ± 6.9% Neonatal Rat Ventricular
Myocyte viability. This is a huge drawback concerning
some applications. At 69 ppm or lower the scaffolds
showed a better viability of 80%. Figure 10 shows the
results of a live/dead cell assay on such scaffolds and
differentiation capabilities indicated by the formation
of sarcomeres (R-actinin = green) and gap junctions
(connexin-43 = red). It inferred that SWCNT embedded
gelatin/chitosan scaffolds performed as an electrical
nanobridge between cardiomyocytes, which affected
electrical coupling, synchronous beating, and car-
diomyocyte function. Excitation conduction velocities
of the nanocomposites were matching with that of the
native myocardial tissue (22 ± 9 cm/s), which can





chitosan details (if available)
Features in comparison to
pristine chitosan materials








average MW of 50,000–
190,000 g/mol with 75%–85%
DDA
• Increased humoral immunity and
significantly induced CD4+ T cell
proliferation upon incorporation
of silica nanoparticles into
chitosan hydrogels
No in vitro examination, only











having a viscosity of 50–
800 mPa, with 80%–95% DDA
• Rapid gelations, improved
rheological behavior (shear
thinning) as well biodegradability





increased up to 6-fold after
5 days of culture.
• Controlled protein release profile
and no cytotoxicity were
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2.5 | Chitosan nanocomposites for
biosensor applications
Biosensors are devices to convert physical, biological, and
chemical signals of biological systems into an electrical
one by identifying exact responses to target analytes.208 A
blood glucose biosensor is a classic example of a typical
biosensor that uses the enzyme Glucose oxidase (GOx).
Electrochemical biosensors, as another example, specifi-
cally react with target moieties and generate an electrical
signal related to specific analyte concentrations, pH, and
temperature.209 Biosensors play a key role in tissue engi-
neering, and chitosan nanocomposites are also well used
in these types of applications. In general, metal
nanoparticles exhibit higher conductivity and electronic
properties than conducting polymer, but the flexibility of
polymers makes them unique for various applications.
The addition of conducting nanoparticles to chitosan
materials enhances the electrical conductivity of the
nanocomposites as well as stimuli-responsive characteris-
tics, which could be used for sensing biological species.210
For specifically enhancing the sensitivity toward biologi-
cal moieties, biosensor surfaces have been modified using
enzymes like cholesterol esterase (ChEt)211 and choles-
terol oxidase (ChOx)212 to detect cholesterol content in
blood or human serums. It has been shown that chitosan
nanocomposites-based biosensors are more efficient,
show a higher sensitivity, and are more durable in com-
parison to pristine chitosan.210,212–218 There are many
nanostructured inorganic materials such as cuprous
oxide nanoparticles,219 Fe3O4 nanoparticles,
218 NiFe2O4
nanoparticle,217 Cerium oxide nanoparticle,220 and TiO2
nanoparticles213 frequently used to enhance the elec-
tronic properties as well as the electrical conductivity of
chitosan based materials in nanocomposites. Application
examples are biosensors to detect cholesterol in human
FIGURE 7 Solution to gel
transformation of various chitosan
nanocomposite formulations:
(A) control chitosan (CS)-
β-glycerophosphate (GP) solution,
(B) control chitosan-
β-glycerophosphate gel, (C) Fe3O4-
bacillus calmettee guérin (BCG)/CS/
GP solution, (D) Fe3O4-BCG-CS/GP
gel, (E) Fe3O4-BCG-CS/GP gels sink
to the bottom of a beaker filled with
saline buffer (F) the gel is attracted
to an external magnet outside the
beaker (Reproduced with permission
from Zhang et al.188)
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blood serum, glucose content in human serum and
immunosensors for ochratoxin-A. Detailed features of
various chitosan nanocomposites in biosensor applica-
tions are summarized in Table 5.
3 | CONCLUSIONS AND FUTURE
PERSPECTIVES
Discussing their limitations is very important for improv-
ing material based explorations and new applications.
Concerning chitosan nanocomposites, an increasing
number of reports suggest that chitosan show great
potential for biomedical applications. Studies portrayed
in this review showcase that responses of tissues are
remarkably different for chitosan nanocomposites in
comparison to individual materials. Surface func-
tionalization of nanoparticles and modifications of
chitosan are important factors for directing cellular
response, adhesion, proliferation, and differentiation.
Moieties such as small biomolecules, peptides, proteins,
and polymers are used to modulate the surface properties
for enhanced biological responses facilitating better cell-
substrate interaction, and improving mechanical proper-
ties of the substrate. Chitosan nanocomposites with tai-
lored properties show favorable outcomes, such as faster
FIGURE 8 (A) Antibody (anti-
CD4) stained section of various
nanocomposite hydrogels placed
inside of rat submucosa of a bladder





CS/GP) provoked more CD4+
activity compared to that of control
chitosan gels with GP,
(B) quantitative determination of
CD4+ T cells per 100
magnification of corresponding




permission from Zhang et al.188)
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TABLE 4 Chitosan nanocomposite substrates for miscellaneous tissue engineering applications
Nanocomposites additives
Fabrication method
and chitosan details (if
available)





















• The prepared clay
nanocomposites showed well










displayed killing rate of more
than 90% and cell walls has
been destroyed rapidly for all
the pathogen.
Manganese dioxide194 Solution casting/85%
DDA
• The fabricated nanocomposite
films performed as super
adsorbent and inhibited




Graphene oxide embedded in




low MW of 144,000 g/
mol with 90% DDA
• Graphene oxide contributed to
enhance the microbial
inhibition, mineral deposition
and in vivo biodegradation
without inflammatory
response of the nanocomposite
films
No in vitro evaluation,







600,000 g/mol with 95%
DDA
• HNT inclusion enhanced the
surface roughness of the films,








• Storage modulus increased by
193% upon incorporation of





derived from crab shells
• Enhanced mechanical
properties, cell metabolic
















average MW having a
viscosity of 0.02–





about 99% bacteria were killed
with high efficiency









• Cell compatibility was also not
affected by an inclusion of







chitosan had 95% DDA
with a Mw of 600,000 g/
mol
• Significant improvement in
thermal stability, modulus and
strength (compression more)









• Biological characteristics such








and chitosan details (if
available)






evaluation (if available) Application
Carbon nanotube embedded





• Carbon nanotube embedded
nanocomposit scaffold
performed as an electrical
nanobridges between
cardiomyocytes, which










velocities similar to that of the
native myocardial tissue (22



































cell line. Cell viability




properties like tensile strength














Adipose derived stem cells
(ADSCs). Cell viability
increased up to 6-fold
after 72 h of culture.
Adipose tissue
engineering








weight with 95% DDA
• Nanocomposite hydrogels
possessed electrically




























viability increased up to
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bone regeneration, targeted drug/cell delivery, better
wound healing, enhanced angiogenesis, and osteogenesis.
Nevertheless, comprehensive studies are necessary before
clinical trials are initiated, since chitosan nanocomposites
may elute over time and there is a need to investigate bio-
distribution in long-term animal trials. More specifically,
nanoparticles released from the nanocomposites may be
taken up by cells through endocytotic pathways, since
nanoparticular graphene sheets have been shown to pen-
etrate cells via clathrin-mediated endocytosis or via
phagocytotic uptake. One already well-known minor
drawback of chitosan is its inferior solubility in neutral
solutions. Additionally, the molecular weight and DD
severely affect the use of chitosan. Recently, one study
extensively investigated the biological characteristics of a
library of chitosans with varying % DD, changes in the
acetylation pattern and varying molecular weights.223 It
was identified that chitosan with more than 30,000 g/mol
blocks glucosamine induced macrophage cytokines by
lysosomal rupturing. Moreover, the concentration or
quantity of nanoparticles used as fillers beyond a certain
wt% decreases cell viability significantly, which is not a
good basis for tissue engineering applications. Specifi-
cally, nanoparticles such as CNTs, silver sulfadiazine,
and bioactive glass have shown toxic effects. Other
nanoparticles did not improve any properties. Cell viabil-
ity after 7 days of culture in presence of chitosan
nanocomposites comprising halloysite nanotubes and
FIGURE 9 Cross sectional morphology of chitosan nanocomposite sponges reinforced with different amounts of silver sulfadiazine
nanoparticles (Reproduced with permission from Shao et al.207)
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FIGURE 10 (A) Live/dead cell assay of neonatal rat ventricular myocytes (NRVM) cultured for 4 days on gelatin blended chitosan-based
nanocomposite scaffolds with varying content (ppm) of single-walled carbon nanotubes (SWCNT) (B) immunostaining of sarcomeres (green for
α-actinin) and gap junctions (red for connexin-43) displaying interconnected and integrated myocytes shows cell spreading upon increasing the
amount of SWCNTs after 7 days of NRVM cell culture. (Adapted from Pok et al.200)
TABLE 5 Chitosan nanocomposite films for biosensors applications
Nanocomposites additives
Fabrication method and
chitosan details (if available)
Features in comparison to pristine
chitosan materials Application






molecular weight with 85%
DDA
• Functionalised nanoparticles reinforced
nanocomposite films showed excellent
biosensing characteristics to detect total
cholesterol content in human blood




• High sensitivity of 0.895 μA/




Solution casting • Showed excellent biosensing
characteristics to detect total glucose
content in human blood serum with
high sensitivity (11.54 μA/cm2/mM),
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calcium phosphate resulted in the same cell viability (%)
as in the control samples. However, despite various flaws
of chitosan nanocomposite substrates, they hold a great
potential for biomedical applications.
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